Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.69 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.69 |
| ▸ | AR | P10275 | 6/20 | 0.69 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630991 | 0.88 | PGR (0.74) | PGRNR3C1NR3C2ARIMPDH2 | |
| SCHEMBL1629438 | 0.85 | PGR (0.80) | PGRNR3C1NR3C2ARSLC22A12 | |
| SCHEMBL1630542 | 0.84 | PGR (0.69) | PGRNR3C1NR3C2ARSLC22A12 | |
| SCHEMBL1630707 | 0.83 | PGR (0.76) | PGRNR3C1NR3C2ARIMPDH2 | |
| SCHEMBL1629914 | 0.83 | PGR (0.70) | PGRNR3C1NR3C2ARSLC22A12 | |
| SCHEMBL1630936 | 0.82 | PGR (0.72) | PGRNR3C1NR3C2ARIMPDH2 | |
| SCHEMBL1631780 | 0.82 | PGR (1.00) | PGRNR3C1NR3C2ARIMPDH2 | |
| SCHEMBL1630206 | 0.82 | PGR (0.71) | PGRNR3C1NR3C2ARSLC22A12 | |
| SCHEMBL1630731 | 0.81 | PGR (0.72) | PGRNR3C1NR3C2ARIMPDH2 | |
| SCHEMBL1631772 | 0.80 | PGR (0.71) | PGRNR3C1NR3C2ARIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | PGR 1/4885NR3C1 63/4885NR3C2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.